Targeted Therapeutics Research Award
Funded equally by LUNGevity Foundation and American Lung Association National Office
Venkateshwar Keshamouni, PhD
University of Michigan
Detroit
MI
Agents that activate the PPARgamma protein have already been used in the treatment of diabetes and atherosclerosis. Dr. Keshamouni is researching whether and how they affect the growth of non-small cell lung cancer (NSCLC) cells.